Brokerages Set vTv Therapeutics Inc. (VTVT) PT at $16.00
vTv Therapeutics Inc. (NASDAQ:VTVT) has been assigned an average recommendation of “Buy” from the six brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $16.00.
A number of brokerages have recently issued reports on VTVT. Stifel Nicolaus reiterated a “buy” rating and set a $12.00 target price on shares of vTv Therapeutics in a research report on Friday, November 3rd. Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 5th. Finally, Citigroup Inc. reiterated an “add” rating on shares of vTv Therapeutics in a research report on Wednesday.
In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was acquired at an average cost of $4.97 per share, with a total value of $49,700.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ronald O. Perelman purchased 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were acquired at an average cost of $4.57 per share, with a total value of $91,400.00. The disclosure for this purchase can be found here. Insiders have bought 80,000 shares of company stock worth $377,100 over the last quarter. 0.80% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in shares of vTv Therapeutics by 6.1% during the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of vTv Therapeutics by 4.8% during the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock worth $418,000 after buying an additional 2,900 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the third quarter worth approximately $481,000. State Street Corp raised its stake in shares of vTv Therapeutics by 2.1% during the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after buying an additional 1,976 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of vTv Therapeutics by 62.7% during the second quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after buying an additional 101,850 shares during the last quarter. 10.93% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/brokerages-set-vtv-therapeutics-inc-vtvt-pt-at-16-00/1695970.html.
Shares of vTv Therapeutics (NASDAQ VTVT) traded down $0.07 during mid-day trading on Wednesday, hitting $5.82. 9,200 shares of the stock were exchanged, compared to its average volume of 30,073. vTv Therapeutics has a 12 month low of $3.57 and a 12 month high of $8.09.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.